LRG protein and ulcerative colitis remission
Part of Digestive system, Immune system & allergy clinical trials.
This study looks at a protein called LRG in your blood or tissue to see if it can tell if your ulcerative colitis is in remission (quiet or not active). This might help doctors better monitor and treat UC in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of ulcerative colitis (UC).
- No other strict requirements—most people with UC may be able to join.
- You'll need to have some tests or biopsies as part of the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study measures a blood protein called LRG and compares it to how active your inflammatory bowel disease (IBD) is during a planned scope procedure. The goal is to see if this blood test could help doctors assess disease activity more easily in the future.
This trial studies people with ulcerative colitis who are in a 'remission-recurrence' state, meaning their symptoms come and go. It aims to better understand this pattern and may help guide future treatments.
This study looks at gut barrier function in people with ulcerative colitis who are in remission. It uses a non-invasive liver test to check for subtle changes in the body.
This study tests whether a substance in your urine can help measure how active your ulcerative colitis is. Researchers hope this simple urine test might become a useful tool to track your disease without more invasive procedures.
This trial tests an investigational drug called LIV001 in people with mild-to-moderate ulcerative colitis. It aims to see if the medicine can help calm inflammation in the colon and improve symptoms.
This study is testing an investigational medication for moderate to severe ulcerative colitis (UC) that has not responded well to other treatments. The goal is to see if the drug can help reduce inflammation and improve symptoms.
Hear when a new Ulcerative Colitis in Histologic Remission trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.